Posted by Michael Wonder on 22 Oct 2021
FDA approves Roche’s Susvimo, a first of its kind therapeutic approach for neovascular or “wet” age-related macular degeneration
22 October 2021 - Susvimo, previously called Port Delivery System with ranibizumab, is the first neovascular age-related macular degeneration treatment in 15 years to provide an alternative to standard of care eye injections needed as often as once a month.
Roche today announced that the U.S. FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration who have previously responded to at least two anti-vascular endothelial growth factor injections.
